Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announces the launch of its new Liver Fibrosis and Kidney Function Discovery Panels.

Chronic liver disease causes two million deaths worldwide every year. Similarly, chronic kidney disease affects nearly 36 million adults in the U.S., with almost nine out of ten patients remaining unaware of their condition. Both diseases are treatable if detected early, but more research is needed to understand these ailments' underlying causes and identify better biomarkers for early detection.

As part of the Metabolon Discover portfolio of metabolomics services, Metabolon's new Liver Fibrosis and Kidney Function Discovery Panels assess multiple metabolites across diverse biological pathways associated with liver fibrosis and kidney disease, providing a greater understanding of these conditions. These new panels also leverage new visualization tools, allowing researchers to compare results across different data sets to identify and understand the impact of statistically significant changes in metabolite abundance.

• Metabolon's Liver Fibrosis Discovery Panel covers 105 metabolites across multiple biological processes associated with liver fibrosis. This new panel gives researchers greater confidence in identifying the appropriate markers connected to liver fibrosis and addresses critical questions regarding mechanistic insights, personalized medicine, and drug discovery and testing.
• Metabolon's Kidney Function Discovery Panel analyzes 84 metabolites associated with biochemical processes affecting kidney function to help researchers differentiate the diverse spectrum of kidney disease. Metabolomic profiling in patients with kidney disease identified several metabolites related to alterations in carbohydrate, amino acid, nucleotide, and lipid metabolism, making metabolic profiling an ideal technology for further kidney research.

"Our new Liver Fibrosis and Kidney Function Discovery Panels seek to reveal fundamental metabolic changes, thereby facilitating our understanding of the underlying mechanisms of these diseases," said Rangaprasad (Ranga) Sarangarajan, Ph.D., Chief Scientific Officer at Metabolon. "Metabolon is committed to providing insights that can ultimately lead to the creation of tools improving patient outcomes through earlier detection, better monitoring, and improved treatments."